Shots:
- Sobi has entered into a definitive agreement to acquire Arthrosi Therapeutics, incl. its asset pozdeutinurad (AR882), expanding its gout pipeline
- As per the deal, Sobi will acquire Arthrosi in an all-cash transaction for $950M upfront & ~$550M in clinical, regulatory & sales milestones; closing is expected in H1’26
- Pozdeutinurad (QD, PO) is an URAT1 inhibitor that is being evaluated in 2 fully recruited global P-III (REDUCE 1 & REDUCE 2) trials for the management of progressive & tophaceous gout, with readouts expected in 2026
Ref: Sobi | Image: Arthrosi |Press Release
Related News: Arthrosi Therapeutics Reports Full Enrolment in P-III (REDUCE 1) Trial of Pozdeutinurad for Gout
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
